A
    c~r,~,
    ~
    U
    ticc7I.s~
    REcV~
    October 26, 2004
    CLERK’S
    ~
    OCT 29
    2004
    Charles E. Matoesian
    STATE
    OF
    ILL~4O~S
    DolIuttOfl
    Control
    Boar
    Division ofLegal Counsel
    Illinois Environmental Protection Agency
    1021
    North Grand Avenue East
    P0 Box 19276
    Spnngfield, Illinois 62794
    Re:
    Wallace v. IEPA, PCB
    02-207 (Air Variance)
    Dear Mr. Matoesian,
    As per condition 3.h. of the Order granting a variance in the above
    referenced matter, MedPointe Healthcare, Inc.
    is submitting this letter as a
    progress report for the period from April
    1, 2004 through September 30,
    2004.
    As noted previously, the Wallace Pharmaceuticals’ name has been
    changed to MedPointe Pharmaceuticals.
    According to the Order, MedPointe is required to report on the progress of
    the development of a suitable alternative to the usage ofethanol in the
    affected processes.
    We are pleased to report that research and development
    ofdirect-compression manufacturing processes has been successful, and do
    not involve the use ofethanol.
    These research efforts should satisf~’
    conditions 3.a., 3.b., and 3.c. ofthe Order, in that the bench-top, pilot, and
    commercial scale processes were successful for these products, and do not
    utilize VOM solvents.
    We continue our research efforts with emphasis being placed on non-VOM
    products and processes for our future product development.
    All new
    pro(:Lucts introduced, or in development, since the effective date ofthe
    variance, have involved the use ofdirect compression or other non-VOM
    processes.
    At this writing, we do not expect that add-on control technology
    will be necessary to achieve compliance with our pre-variance limits of 12.5
    tons per year.
    At this writing, we expect our VOM emissions to be well below both the
    allowable variance limit of 25 tons per year, and our pre-variance limit of
    434
    North
    Morgan
    Street, Decatur, IL 62523-1125
    217-424-8400
    www.medpointepharma.com
    tons per year.
    Our VOM emissions for 2003
    were indeed well below
    that level.
    As a result ofour successful process developments, combined with our
    current product portfolio which is primarily manufactured with non-VOM
    processes, we will be
    scheduling a meeting in the near future with you to
    discuss the process ofwithdrawing this variance.
    I trust this brief letter report satisfies the Order requirement for a progress
    report. If any additional information is required please advise.
    Sincerely,
    William J. Taraszewski, Ph.D.
    Director, Pharmaceutical Production
    cc:
    Dorothy
    Gunn,
    Clerk
    Illinois
    Pollution
    Control
    Board
    State
    of
    Illinois
    Center
    IOU
    West
    Randolph
    St..,
    Suite
    11-500
    Chicago,
    IL
    60601
    bc:.
    Mr.
    Paul Edick
    Mr.
    Will Robinson
    Ms.
    Beth
    Hecht
    Ms.
    LaDonna
    Drive
    Mr.
    Rick Majos

    Back to top